Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute lymphoblastic leukaemia.

Ching-Hon Pui1, Leslie L Robison, A Thomas Look

  • 1Department of Oncology, St Jude Children's Research Hospital and University of Tennessee Health Science Center, Memphis, TN 38105, USA. ching-hon.pui@stjude.org

Lancet (London, England)
|March 25, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reactivation of a TAL1 progenitor cell enhancer region by non-coding somatic variants in T-lineage acute lymphoblastic leukemia.

bioRxiv : the preprint server for biology·2026
Same author

Transcription factor cooperativity at a GATA3 tandem DNA sequence determines oncogenic enhancer-mediated activation.

Cell reports·2026
Same author

Multitargeted Reduction of Inflammation and Atherosclerosis in <i>Tet2</i> -deficient CHIP via XPO1 Inhibition and Atf3 restoration.

bioRxiv : the preprint server for biology·2025
Same author

KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma.

bioRxiv : the preprint server for biology·2025
Same author

Transcription factor cooperativity at a GATA3 tandem DNA sequence determines oncogenic enhancer-mediated activation.

Cell reports·2025
Same author

Accurate Measurement of Cell Number-Normalized Differential Gene Expression in Cells Treated With Retinoic Acid.

Bio-protocol·2024
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Acute lymphoblastic leukaemia (ALL) affects children and adults. Research focuses on targeted therapies and improved treatments to increase cure rates and reduce side effects.

Area of Science:

  • Hematology
  • Pediatric Oncology
  • Molecular Biology

Background:

  • Acute lymphoblastic leukaemia (ALL) is a common lymphoid progenitor cell malignancy in children and adults.
  • Current treatments achieve over 80% cure rates in children but have significant toxicities.
  • Understanding ALL's pathobiology is crucial for developing less toxic, more effective therapies.

Purpose of the Study:

  • To explore innovative treatment strategies for ALL that maintain survival gains while minimizing side effects.
  • To investigate the potential of molecularly targeted therapies based on genetic defects in leukaemic cells.
  • To improve cure rates in adults and high-risk pediatric ALL subgroups.

Main Methods:

  • Review of current treatment outcomes and toxicities in pediatric and adult ALL.

Related Experiment Videos

  • Analysis of emerging molecular technologies and their application to ALL pathobiology.
  • Ongoing studies investigating ALL genesis, risk factors, and novel therapeutic regimens.

    • Main Results:

    • High cure rates (>80%) are achievable in pediatric ALL with intensive regimens.
    • Molecular advances offer potential for targeted therapies against specific genetic defects.
    • Adult and high-risk pediatric ALL populations still have suboptimal cure rates.

    Conclusions:

    • Targeted therapies hold promise for revolutionizing ALL management by addressing specific genetic defects.
    • Further research is needed to optimize treatment for adults and high-risk pediatric ALL.
    • Balancing efficacy with reduced toxicity is a key goal for future ALL treatment strategies.